Analytical Data
-
Gene name
PSCA
- Application
-
Alternative Names
PSCA; UNQ206/PRO232; Prostate stem cell antigen
-
Species
Mouse
-
Source
Yeast
-
Tag
N- His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P57096
-
Expression Region
21-95aa
-
Molecular Weight
10.4 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The research on PSCA (Prostate Stem Cell Antigen) recombinant proteins is rooted in the need to better understand prostate cancer and identify potential therapeutic targets. PSCA is a glycosylphosphatidylinositol (GPI)-anchored protein that is predominantly expressed in prostate tissue and is associated with the regulation of cell growth and proliferation. Studies have shown that PSCA expression is significantly upregulated in prostate cancer as compared to normal prostate tissues, making it a potential biomarker for diagnosis and prognosis. The production of recombinant PSCA proteins allows researchers to investigate their structural properties and biological functions more effectively. This research is crucial for developing targeted therapies, as PSCA might play a role in tumorigenesis and cancer progression. Additionally, understanding the interactions between PSCA and other cellular pathways could open avenues for novel therapeutic strategies. Therefore, the study of PSCA recombinant proteins not only enhances our comprehension of prostate cancer biology but also has implications for the development of immunotherapeutic approaches aimed at targeting PSCA in cancer treatment.
